study biopharma - Robuta Search

https://www.biopharmadive.com/news/gritstone-covid-vaccine-trial-project-nextgen/695027/ Gritstone wins ‘Project NextGen’ funding to run head-to-head COVID vaccine study | BioPharma Dive In a note to clients, Evercore ISI analyst Jonathan Miller described the Project NextGen contract for Gritstone as “certainly a nice signal of continued... covid vaccine study biopharma wins funding run https://www.biopharmadive.com/news/cidara-stock-soars-as-antiviral-drug-succeeds-in-flu-study/751286/ Cidara stock soars as antiviral drug succeeds in flu study | BioPharma Dive Company shares doubled on Phase 2 study results suggesting its drug could become an alternative to vaccines for flu prevention. stock soars study biopharma antiviral drug succeeds https://www.biopharmadive.com/news/lilly-verzenio-survival-data-breast-cancer-monarche-study/758751/ Lilly says breast cancer drug extended survival in study | BioPharma Dive Treatment with Verzenio helped people with a common type of early breast cancer liver longer than those given standard hormone therapy. breast cancer study biopharma lilly says drug https://www.biopharmadive.com/news/moderna-combo-vaccine-flu-covid-trial-success/718431/ Moderna says combination flu, COVID shot succeeds in study | BioPharma Dive Positive results from the trial could position Moderna to bring the two-in-one vaccine to market in 2025. covid shot study biopharma moderna says combination https://www.biopharmadive.com/news/merck-lagevrio-covid-prevention-fail-study/643153/ Merck’s COVID-19 treatment falls short in prevention study | BioPharma Dive The antiviral Lagevrio did not significantly reduce the risk of getting COVID-19 following household exposure to someone infected by the coronavirus. falls short study biopharma covid treatment prevention https://www.biopharmadive.com/news/pfizer-hemophilia-b-gene-therapy-spark-bleeding/639477/ Pfizer says hemophilia B gene therapy controlled bleeding in key study | BioPharma Dive The Phase 3 results showed the one-time treatment outperformed standard factor replacement in adults with the bleeding disorder, but suggest it may be less... gene therapy study biopharma pfizer says hemophilia https://www.biopharmadive.com/news/spyre-inflammatory-bowel-disease-drug-results-a4b7/817298/ Spyre drug for inflammatory bowel disease shows promise in early study | BioPharma Dive The therapy, which works similarly to Takeda’s blockbuster Entyvio, showed remission rates that suggest a “best-in-class” profile, the company said. inflammatory bowel disease shows promise study biopharma drug early https://www.biopharmadive.com/news/structure-obesity-pill-drug-trial-results-weight-loss/717768/ Structure pill leads to competitive weight loss in obesity study | BioPharma Dive Shares in the company soared by more than 50% as study data showed the pill led to similar levels of weight loss as a rival drug being developed by Eli Lilly. weight loss study biopharma structure pill leads https://www.biopharmadive.com/news/vir-flu-antibody-negative-study-results/688503/ Vir, struggling to build on COVID success, says flu antibody fails key study | BioPharma Dive The setback cut shares of the once high-flying infectious disease drug developer in half, adding to the challenge facing new CEO Marianne De Backer. study biopharma vir struggling build covid https://www.biopharmadive.com/news/gsks-antibiotic-gonorrhea-study-results-gepotidacin/708471/ GSK drug meets goal in late-stage gonorrhea study | BioPharma Dive The drug, one of several GSK is developing for drug-resistant bacteria, has now succeeded in testing against two different infections. late stage study biopharma gsk drug meets https://www.biopharmadive.com/news/moderna-cytomegalovirus-vaccine-study-failure/803560/ Moderna says CMV vaccine once seen as future blockbuster fails key study | BioPharma Dive A shot analysts projected as a multibillion-dollar seller produced results “well below” the company’s expectations, heightening pressure on Moderna’s flagging... study biopharma moderna says cmv vaccine https://www.biopharmadive.com/news/bayer-elinzanetant-endocrine-breast-cancer-study-results/736906/ Bayer says menopause drug succeeds in breast cancer study | BioPharma Dive The results suggest Bayer’s elinzanetant may help a broader group of women with vasomotor symptoms, which are associated with menopause as well as a common... breast cancer study biopharma bayer says menopause https://www.biopharmadive.com/news/pfizer-rsv-vaccine-monet-younger-adults-trial/712651/ Pfizer, with new study results, seeks to bring RSV shot to adults aged 18-59 | BioPharma Dive The company plans to submit the trial data to regulators in a bid to win approval of its vaccine Abrysvo in adults as young as 18 years old. new study pfizer results seeks bring https://www.biopharmadive.com/news/moderna-flu-covid-combo-vaccine-study-results/695570/ Moderna claims positive results in early study for combo COVID, flu shot | BioPharma Dive The company is planning to start a Phase 3 trial of the vaccine this year, and is targeting a regulatory approval in 2025. positive results covid flu moderna claims early https://www.biopharmadive.com/news/moderna-flu-vaccine-study-results/643030/ Moderna shares sink on mixed study results for flu vaccine | BioPharma Dive The company’s shot sparked a strong enough immune response against only one of two groups of influenza strains it was tested against in a closely watched Phase... study results flu vaccine moderna shares sink https://www.biopharmadive.com/news/vir-astellas-masked-t-cell-engager-prostate-cancer-results/812950/ Vir climbs on Astellas deal, study results for ‘masked’ T cell engager | BioPharma Dive According to one analyst, the alliance and early data “validate” the oncology work of Vir, which was once purely an infectious disease specialist before... study results vir climbs astellas deal https://www.biopharmadive.com/news/amgen-subcutaneous-tepezza-thyroid-eye-disease-results/816708/ Under-the-skin Tepezza comparable to infused version in key study, Amgen says | BioPharma Dive The findings could help Amgen defend Tepezza’s market-leading position against emerging rivals, though some analysts expressed doubt about its competitive... skin comparable infused version key https://www.biopharmadive.com/news/johnson-johnson-nipocalimab-trial-hdfn-momenta/642073/ J&J says drug it acquired from Momenta succeeds in study of ultra-rare condition | BioPharma Dive says drug acquired momenta succeeds